Messenger App for Windows and Mac Will Shut Down Later This Year Meta says it will deprecate the app on Dec. 15, at which point 'you’ll be blocked' from using it and should delete it from your ...

Replimune received FDA acceptance for its RP1 BLA resubmission in advanced melanoma, with a PDUFA date set for April 2026. REPL stock surged nearly 100% on the news, but FDA acceptance only restarts ...

Aaron covers what's exciting and new in the world of home entertainment and streaming TV. Previously, he wrote about entertainment for places like Rotten Tomatoes, Inverse, TheWrap and The Hollywood ...

Meta is shutting down its Messenger app for macOS and Windows and pushing users to the web. Meta confirmed over email to Engadget that the app will be fully shutdown on December 15, after which the ...

Meta has published a support doc that states its Messenger app for Mac is being discontinued. New users won’t be able to download the app at all, and existing users have about 60 more days of use ...

Meta is shutting down Messenger’s stand-alone desktop apps for Windows and Mac on December 15, the company confirmed to TechCrunch on Thursday. Starting December 15, users will no longer be able to ...

If you're using Messenger on macOS, you'll want to switch to something else — and probably sooner, rather than later. According to a pair of Facebook Help Center page, Facebook is axing its Desktop ...

Before everyone had a smartphone in their pocket and access to countless free mobile games (both good and hot messes), people got their free gaming fixes from browser games. I have fond memories of ...

On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...

The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...

Replimune (NASDAQ:REPL) shares fell sharply after the company said it has yet to determine the accelerated approval pathway for its lead drug RP1, following a recent meeting with the U.S. FDA.